PT - JOURNAL ARTICLE AU - Wu, Dong AU - Zhang, li AU - Qiang, Yuzhen AU - Wang, Kaiyu TI - Improved detection of <em>SBDS</em> gene mutation by a new method of next-generation sequencing analysis based on the Chinese mutation spectrum AID - 10.1101/2021.09.03.21263106 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.03.21263106 4099 - http://medrxiv.org/content/early/2021/09/17/2021.09.03.21263106.short 4100 - http://medrxiv.org/content/early/2021/09/17/2021.09.03.21263106.full AB - Next-generation sequencing (NGS) is a useful molecular diagnostic tool for genetic diseases. However, due to the presence of highly homologous pseudogenes, it is challenging to use short-read NGS for analyzing mutations of the Shwachman-Bodian-Diamond syndrome (SBDS) gene. The SBDS mutation spectrum was analyzed in the Chinese population, which revealed that SBDS variants were primarily from sequence exchange between SBDS and its pseudogene at the base-pair level, predominantly in the coding region and splice junction of exon two. The c.258+2T&gt;C and c.185_184TA&gt;GT variants were the two most common pathogenic SBDS variants in the Chinese population, resulting in a total carrier frequency of 1.19%. When analyzing pathogenic variants in the SBDS gene from the NGS data, the misalignment was identified as a common issue, and there were different probabilities of misalignment for different pathogenic variants. Here, we present a novel mathematical method for identifying pathogenic variants in the SBDS gene from the NGS data, which utilizes read-depth of the paralogous sequence variant (PSV) loci of SBDS and its pseudogene. Combined with PCR and STR orthogonal experiments, the results of SBDS gene mutation analysis were improved in 40% of clinical samples, and various types of mutations such as homozygous, compound heterozygous, and uniparental diploid were explored. The findings effectively reduce the impact of misalignment in NGS-based SBDS mutation analysis and are helpful for the clinical diagnosis of SBDS-related diseases, the research into population variation, and the carrier screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received approval from the ethics committee of No. 900 Hospital of the Joint Logistics Team.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are either included in the article (or in its supplementary files) or available from the corresponding author on reasonable request. The data are not publicly available due to privacy or ethical restrictions.